Halo vs Flow Neuroscience | Technology & Clinical Use

Halo vs. Flow - What's the Difference?

Halo is part of the Flow Neuroscience group, and both develop advanced neuromodulation technology but for different purposes.

Halo is a wellness and performance device designed to enhance mood, sleep, and focus in healthy adults.

Flow is a medical device developed for the treatment of depression in the UK and EU.

Both use identical tDCS hardware, stimulating the left dorsolateral prefrontal cortex (DLPFC) with a 2 mA current.

The key difference lies in their intended use and certification.

Product Overview

Halo
Performance & Wellness

Smaller doses, broken down into
more manageable protocols for busy schedules
Protocols optimised depending on whether priority is focus, mood or sleep [coming soon]
Performance and wellness optimisation content designed for healthy people who want an edge
Wellness device

Flow
Clinical Treatment

Higher doses, focused entirely on treatment of mod-severe depression
Remote monitoring software enabling clinicians to track outcomes and customise the dose
Behavioural therapy content aimed at putting in place healthy foundational behaviours
Medical device

The Technology

Both Halo and Flow deliver gentle, clinically tested transcranial direct current stimulation (tDCS) to the DLPFC - the brain’s control hub for emotion, focus, and sleep regulation.

While the hardware and stimulation parameters are identical, Halo is optimized for performance and wellness, while Flow’s software and protocols are designed for clinical treatment.

Halo

Device Type: Wellness device
tDCS Current: 2 mA to left DLPFC
Primary Purpose: Mood, sleep, and focus optimization
User: Healthy adults
Content: Performance and wellness programs
Regulatory Status: Wellness product (US)

Flow

Device Type: Medical device (CE certified)
tDCS Current: 2 mA to left DLPFC
Primary Purpose: Treatment of depression
User: Patients with diagnosed depression
Content: Behavioural therapy modules
Regulatory Status: Medical device (UK/EU)

Outcomes

Halo

Real-world data from healthy users shows:

73% report improved mood after 2 weeks
71% report better sleep after 4 weeks
70% report sharper focus after 4 weeks

Flow

Clinical results from patient studies show:

Clinical studies show 57% of users no longer meet criteria for depression after 10 weeks, and 77% experience improvement within 3 weeks.

Both are built on decades of tDCS research - with independent studies demonstrating positive effects on mood, sleep, and focus across both healthy and clinical populations.

Access

Halo: Available now for $599.

Join community of high performers and wellness enthusiasts using tDCS to improve mood, sleep and focus.

Try Halo

Flow: Currently going through the FDA PMA process.

Once the process is complete, if successful, Flow would be available via prescription as a Class III medical device for the treatment of unipolar depression in the US.